Model and function of the magnifying endoscopeMagnifying endoscopes (CF-200Z, PCF-Q240ZI, CF-Q240ZL/I; manufactured by Olympus, Tokyo, Japan) are applicable for 80-100 times magnified observation. Using CF-200Z and PCF-Q240ZI, magnification is controlled by manual strokes, but CF-Q240ZL/I is equipped with an electronic zoom, and the magnification can be controlled by the easy operation of a hand or foot switch.
Practice and safety of magnified observation by dye spraying methodsIn the dye contrast method, 0.1-0.4% indigocarmine dye is sprayed over the lesion, and the pattern of indigocarmine dye that is retained in the crypt is recognized as the pit. However, indigocarmine dye is not well-retained in pits smaller than the normal pit, and type IIIs and small type V glands cannot be observed in this way. 20 In the dye staining method, the nuclei and cytoplasm of intestinal tract surface epithelial cells are stained by applying 0.05-0.1% crystal violet to the lesion, and observing the pattern of non-stained crypt as a pit. 20 Although it is not clear whether the pit observed is formed by staining of the nuclei or cytoplasm, the fact that the border observed differs between the contrast and staining methods suggests that a pit formed by the staining method is formed by nuclear staining (Fig. 2a,b). Crystal violet (methylrosanilinium chloride) was synthesized as a triphenylmethanaminium dye around 1860. It is a selective bactericidal agent that was used for the treatment of gram-positive bacteria by Stilling et al. 21 in 1890. In 1930, Faust used it as an anthelminthic for stercoral strongyloides, and it was used as an anthelminthic for oxyuris vermicularis in 1940. It is not currently used for the treatment of parasites, but rather as a bactericidal disinfectant. 21 Recently, it has been attracting attention as a local therapeutic agent for methicillin-resistant Staphylococcus aureus. Therefore, in regard to carcinogenensis and toxicity, there may be no problem in terms of safety when crystal violet is used. 22,23 Digestive Endoscopy (2001) 13 (Suppl.), S10-S13
SESSION 1, PART 1: MODERATOR'S COMMENT